Reactivation of retinopathy of prematurity after bevacizumab injection.
about
Pharmacologic interventions for the prevention and treatment of retinopathy of prematurityScreening and Treatment in Retinopathy of PrematurityAsymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.Adenosine receptors and caffeine in retinopathy of prematurity.Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?[Current therapeutic options in retinopathy of prematurity].Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5.Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.Intravitreal injection of bevacizumab for retinopathy of prematurity.Intravitreal injection of bevacizumab for retinopathy of prematurity in an infant with peters anomalyVascular endothelial growth factor antagonist therapy for retinopathy of prematurityPosterior pole sparing laser photocoagulation combined with intravitreal bevacizumab injection in posterior retinopathy of prematurity.Retinopathy of prematurity: New developments bring concern and hope.A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage.Outcome of solid-state 532 nm green laser in high-risk retinopathy of prematurity at a tertiary care centre in India.Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathyAdenosine A1 Receptors Selectively Modulate Oxygen-Induced Retinopathy at the Hyperoxic and Hypoxic Phases by Distinct Cellular Mechanisms.Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.Emerging roles for antiangiogenesis factors in management of ocular disease.Retinopathy of prematurity: An update on screening and managementAnti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurityShort hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity.Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy.Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.Mechanisms and management of retinopathy of prematurity.Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureVEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesisClinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.Advances in understanding and management of retinopathy of prematurity.An Update on Retinopathy of Prematurity (ROP).Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy.Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
P2860
Q26772889-114D2213-B0E2-489B-A909-7EE0217D19E6Q28082541-C5AE7F76-D5D9-408B-875A-F5CC4FB58C72Q33561241-9062061F-DA14-4CE3-A544-B584F84C07F1Q33860622-BB782440-40FB-4CD5-A168-CAEB6DE3E241Q34339456-D4343CA5-CB10-401A-824A-3FDF9DE5EEE8Q34501395-D045D788-BC2F-43F9-824C-777D135A2C5CQ34523362-C2834EB3-7C4D-41F2-83A0-8912C91BFE43Q34544365-0C90DA40-56D7-4FEC-A0AD-CBA26FB79103Q34778243-E004CF62-B83A-420E-8A17-FEBEF88BC9AEQ35102460-5C86D00D-7F6E-4BD1-B69B-DAE639E0D4ABQ35435581-E66231CC-5BB0-4AD6-AA93-44A29B912401Q35473907-B9E89DC5-4DB4-4D37-AC48-2472C10AA03DQ35547787-F306A6C0-E799-47AE-8D63-F4208D8042ECQ35574624-53587A24-0105-46D6-86A2-3A50E16DBDB4Q35665701-1E53046C-FEF0-487F-ACFD-1E1BD1D0DDC1Q35846321-C90DC9EA-116D-427B-928F-200EFBB363FAQ35969307-5A00F182-81CF-4573-B6CC-E7DFB41CEF9CQ35984783-CB307189-CDDB-4135-85B2-2644760C1C28Q36052210-4D1ADF8A-8535-4E99-8E5D-10468A334883Q36078573-E469E5B5-EDC7-4251-8FB6-0DAA3E9ACBD5Q36245132-0B22B633-0696-40FC-BB54-C11D4A1B15BEQ36282110-726C1579-D812-4F59-A8D3-04640F15EC58Q36379513-C24B3221-B59F-476E-B576-2ACF4F948DD5Q36424969-16A41AD3-5A0F-44F1-B8E2-DF74DF2D4B57Q36686806-DEAB19C7-2A7A-486C-90E9-14F2547DC3DFQ36696513-79F361DA-B7BD-4470-BE2B-7CF14926E015Q36728908-D3F4EC83-E013-4F71-AFF5-C7D717742F20Q36752978-77B8FFF6-F206-4FDE-91B1-2E702E1287CCQ37149035-93237F2A-8EB7-4BEC-BE14-38E4D19F47C4Q37274155-89369A4C-B588-4BC0-8434-DF93CEC86A11Q37561227-D5C72CFD-3EB1-4EE5-AC3D-FBFDADDFD3F7Q37577214-F4EA6AF1-1AD2-42FD-BA42-DD1C7DF0325DQ38069895-9A958CEE-A1EB-4EA6-B38D-38D8DA619905Q38110731-DB0EB565-6CF3-4426-9B2B-511F4E25DC1CQ38560836-CDF66427-59CD-4BB1-A309-F35776F154C6Q38848653-DA689E8B-1EC5-4F23-8B11-B5FB9F4B07DCQ39052915-C275DD20-87E5-4C88-BA7D-2787B42170BAQ39413013-BD20C501-194F-438F-BB52-E2E9AD475B4AQ41100793-763D36B4-F241-4F9B-AA63-5DB08E582849Q45147023-25E1D2DC-B4EB-4EC1-8596-81C94668C3D4
P2860
Reactivation of retinopathy of prematurity after bevacizumab injection.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Reactivation of retinopathy of prematurity after bevacizumab injection.
@ast
Reactivation of retinopathy of prematurity after bevacizumab injection.
@en
Reactivation of retinopathy of prematurity after bevacizumab injection.
@nl
type
label
Reactivation of retinopathy of prematurity after bevacizumab injection.
@ast
Reactivation of retinopathy of prematurity after bevacizumab injection.
@en
Reactivation of retinopathy of prematurity after bevacizumab injection.
@nl
prefLabel
Reactivation of retinopathy of prematurity after bevacizumab injection.
@ast
Reactivation of retinopathy of prematurity after bevacizumab injection.
@en
Reactivation of retinopathy of prematurity after bevacizumab injection.
@nl
P2093
P1433
P1476
Reactivation of retinopathy of prematurity after bevacizumab injection.
@en
P2093
Jennifer Hu
John M Galasso
Michael J Shapiro
Michael P Blair
Rashmi Kapur
Steven J Lichtenstein
P304
P356
10.1001/ARCHOPHTHALMOL.2012.592
P407
P577
2012-08-01T00:00:00Z